Ann: Annual Report to shareholders, page-113

Warning: rationalising my investment decision

Current:

No doubt this company will definitely be worth more than where it is currently priced EVEN given the potential of the initial targeted market.

REAL Potential:

The baby app will be the blue sky. As a new parent, my 15 month has been crying and unwell due to throat infection and infected ear canal (joys of childcare). We have been feeding him Panadol for children, and to be able to know the severity of pain and knowing that the pain is being managed, I would pay any price to get that peace of mind. Instead I called in the Home GP numerous times and even took him to emergency once (3am) to turn back due to the extended wait time. Imagine if you own the app or if the healthcare professional has access to that app to be able to see the real level of pain and that it is being managed effectively.

The real test is whether this algo works. IMO paediatric is the holy grail for health apps however therein also lies many challenges associated with knowing how to accurately work out how to score pain severity on babies who by definitely also unable to verbalise pain, I.e difficult to have a comparator.

Long term view:
As many has stated here before and PD interview. This is a slow burner due to the go to market model adopted by management and the fact that the company wishes to include Pain as a one of the vital signs similar to blood glucose. This will be a challenge and the successful adoption of which will be phenomenal.

Short term view:
I have been wanting to sell and buy back in, in order to increase position sizing for my fixed capital but haven't been able to pull that trigger. I am not a trader but the idea of reducing cost base(increasing sizing) is so damn alluring.